

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number  
**WO 02/056026 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/68**,  
G06F 19/00, G01N 33/567, 33/543

(21) International Application Number: **PCT/JP02/00029**

(22) International Filing Date: **9 January 2002 (09.01.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
60/260,433 9 January 2001 (09.01.2001) US  
60/272,981 2 March 2001 (02.03.2001) US  
10/038,918 3 January 2002 (03.01.2002) US

2-chome, Chuo-ku, Tokyo 103-8405 (JP). **LEE, Lyang-ja**; c/o Mitsubishi Pharma Corporation, Tokyo Head Office, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8405 (JP). **MUKAI, Hiromichi**; c/o Mitsubishi Pharma Corporation, Tokyo Head Office, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8405 (JP). **MUNECHIKA, Koji**; c/o Mitsubishi Pharma Corporation, Tokyo Head Office, 2-6, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8405 (JP). **ARIKUNI, Hisashi**; c/o SC BIOSCIENCES CORPORATION Kamakura Laboratory, 200, Kajiwara, Kamakura-shi, Kanagawa 247-0063 (JP). **SHIWA, Mieko**; c/o SC BIOSCIENCES CORPORATION Kamakura Laboratory, 200, Kajiwara, Kamakura-shi, Kanagawa 247-0063 (JP). **OCHIAI, Bungo**; c/o SC BIOSCIENCES CORPORATION Kamakura Laboratory, 200, Kajiwara, Kamakura-shi, Kanagawa 247-0063 (JP).

(71) Applicant: **MITSUBISHI PHARMA CORPORATION** [JP/JP]; 6-9, Hiranomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-0046 (JP).


(74) Agent: **TAKASHIMA, Hajime**; Fujimura Yamato Seimei Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0044 (JP).

(72) Inventors: **TANAKA, Kenji**; c/o Mitsubishi Pharma Corporation, Tokyo Head Office, 2-6, Nihonbashi-honcho

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

[Continued on next page]

(54) Title: **NOVEL PROTEOME ANALYSIS METHOD AND DEVICES THEREFOR**



(57) Abstract: The present invention provides a proteome analysis method including grouping a proteome into membrane proteins and compounds capable of interacting with the membrane proteins, while retaining their native structure and function, and analyzing both the membrane proteins and the compounds based on biological affinity, and devices therefor.

WO 02/056026 A1



CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- with amended claims

**Date of publication of the amended claims:**

19 September 2002

- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## AMENDED CLAIMS

[received by the International Bureau on 31 July 2002 (31.07.02);  
new claims 18-28 added; remaining claims unchanged (2 pages)]

18.(added) A library of membrane proteins embedded in liposome.

19.(added) The library of claim 18, wherein the membrane  
proteins comprise at least GPI anchor type receptors, G  
5 protein-coupled receptors, and oligomer type receptors.

20.(added) The library of claim 18, wherein the membrane  
protein-embedded liposome has a diameter of 10 to 5,000 nm.

10 21.(added) The library of claim 18, wherein the membrane  
protein-embedded liposome has a diameter of 10 to 500 nm.

22.(added) The method of claim 1, wherein the compounds are  
ligands and the membrane proteins are receptors.

15

23.(added) The method of claim 1, wherein the compounds are  
water-soluble proteins, and the method comprises the steps of:

- (1) isolating a water-soluble protein fraction from a  
biological sample, separating water-soluble proteins in the  
20 fraction by gel electrophoresis, bringing the gel after  
electrophoresis into contact with a ligand support having a  
surface that can immobilize the proteins retaining the  
physiological function, and transferring the water-soluble  
proteins in the gel onto the ligand support;
- 15 (2) isolating a membrane fraction from a cell sample and fusing  
the membrane fraction with liposomes to prepare a membrane  
protein library wherein all membrane proteins are attached to  
or penetrated into its lipid bilayer;
- (3) bringing the water-soluble proteins immobilized on the  
20 ligand support in contact with the membrane protein library to  
trap membrane proteins having affinity to the water-soluble  
proteins on the ligand support; and
- (4) analyzing both or either of the membrane proteins and the  
water-soluble proteins having affinity by a means capable of

analyzing at least one of the physical or chemical properties of those proteins.

24.(added) The support of claim 6, wherein the compounds are  
5 ligands other than antibodies and the membrane proteins are  
receptors.

25.(added) The plate of claim 11, wherein the compounds are  
ligands other than antibodies and the membrane proteins are  
10 receptors.

26.(added) The method of claim 12, wherein the proteome  
analysis method is the method defined in claim 2 or 3.

15 27.(added) The method of claim 13, wherein the method applied  
is the method of claim 26.

28.(added) The method of claim 15, wherein the proteome  
analysis is performed according to the method of claim 2 or 3.